авторефераты диссертаций БЕСПЛАТНАЯ БИБЛИОТЕКА РОССИИ

КОНФЕРЕНЦИИ, КНИГИ, ПОСОБИЯ, НАУЧНЫЕ ИЗДАНИЯ

<< ГЛАВНАЯ
АГРОИНЖЕНЕРИЯ
АСТРОНОМИЯ
БЕЗОПАСНОСТЬ
БИОЛОГИЯ
ЗЕМЛЯ
ИНФОРМАТИКА
ИСКУССТВОВЕДЕНИЕ
ИСТОРИЯ
КУЛЬТУРОЛОГИЯ
МАШИНОСТРОЕНИЕ
МЕДИЦИНА
МЕТАЛЛУРГИЯ
МЕХАНИКА
ПЕДАГОГИКА
ПОЛИТИКА
ПРИБОРОСТРОЕНИЕ
ПРОДОВОЛЬСТВИЕ
ПСИХОЛОГИЯ
РАДИОТЕХНИКА
СЕЛЬСКОЕ ХОЗЯЙСТВО
СОЦИОЛОГИЯ
СТРОИТЕЛЬСТВО
ТЕХНИЧЕСКИЕ НАУКИ
ТРАНСПОРТ
ФАРМАЦЕВТИКА
ФИЗИКА
ФИЗИОЛОГИЯ
ФИЛОЛОГИЯ
ФИЛОСОФИЯ
ХИМИЯ
ЭКОНОМИКА
ЭЛЕКТРОТЕХНИКА
ЭНЕРГЕТИКА
ЮРИСПРУДЕНЦИЯ
ЯЗЫКОЗНАНИЕ
РАЗНОЕ
КОНТАКТЫ


Pages:     | 1 |   ...   | 4 | 5 || 7 |

«КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ Ассоциация ревматологов России Научное общество гастроэнтерологов России Российское межрегиональное ...»

-- [ Страница 6 ] --

305. Taha A., Angerson W., Knill-Jones R., 317. Bjorkman D.J., Kimmey M.B. Nonsteroidal Blatchford O. Upper gastrointestinal mucosal antiinflammatory drugs and gastrointestinal dis abnormalities and blood loss complication low- ease: pathophysiology, treatment and prevention.

dose aspirin and antithrombotic therapy. Aliment Dig Dis 1995;

13:119—29.

Pharmacol Ther 2006;

23:489—95. 318. Davenport H. The gastric mucosal barrier.

306. Larsen K., Stray N., Engh V., Sandnes D. Digestion 1972;

5:162—5.

Esophageal lesions associated with diphospho- 319. Rich M., Scheiman J. Nonsteroidal anti nates. Tidsskr Nor Laegeforen 2000;

120:2397—9. inflammatory drug gastropathy at the new millen 307. Luciani J., Pigatto V., Naves A. et al. nium: mechanisms and Prevention. Semin Esophagitis associated with use of alendronate in Arthritis Rheum 2000;

30:167—79.

5 postmenopausic patients. Acta Gastroenterol 320. Soll A. Pathogenesis of nonsteroidal anti Latinoam 2001;

31:59—63. inflammatory drug-related upper gastrointestinal 308. Biswas P., Wilton L., Shakir S. toxicity. Am J Med 1998;

105:10—6.

321. Taha A., Angerson W., Nakshabendi I. Intern Med 1998;

158:33—9.

Gastric and duodenal mucosal blood flow in 332. Laporte J., Ibanez L., Vidal X. et al. Upper patients receiving non-steroidal anti-inflammato- gastrointestinal bleeding associated with the use of ry drugs--influence of age, smoking, ulceration NSAIDs: newer versus older agents. Drug Safety and Helicobacter pylori. Aliment Pharmacol 2004;

27:411—20.

Ther 1993;

7:41—5. 333. Wolfe F., Hawley D. The comparative risk 322. Wallace J. Mechanism of protection and and predictors of adverse gastrointestinal events in healing: current knowledge and future research. rheumatoid arthritis and osteoarthritis: a prospec Am J Med 2001;

110:19—23. tive 13 year study of 2131 patients. J Rheumatol 323. Vergara M., Catalan M., Gisbert J., Calvet X. 2000;

27:1668—73.

Meta-analysis: role of Helicobacter pylori eradi- 334. Fries J., Kristen N., Bennet M. et al. The cation in the prevention of peptic ulcer in NSAID rise and decline of nonsteroidal anti-inflammato users. Aliment Pharmacol Ther 2005;

21:1411—8. ry drag-associated gastropathy in rheumatoid 324. Papatheodoridis G., Archimandritis A. Role arthritis. Arthritis Rheum 2004;

50:2433-40.

of Helicobacter pylori eradication in aspirin or 335. Fries J. Non-steroidal anti-inflammatory non-steroidal anti-inflammatory drug users. drug safety: a view from the _RAMIS databank.

World J Gastroenterol 2005;

11:3811—6. Curr Opin Rheumat 1996;

9:3—7.

325. Huang J., Sridhar S., Hunt R. Role of 336. Singh G. Recent consideration in nons Helicobacter pylori infection and non-steroidal teroidal anti-inflammatory drug gastropathy. Am J anti-inflammatory drugs in peptic-ulcer disease: a Med 1998;

105:31—8.

meta-analysis. Lancet 2002;

359:14—22. 337. Allison M., Howatson A., Torrance C. et al.

326. Tzourmakliotis D., Economou M., Gastrointestinal damage associated with the use Manolakopolos S. Clinical significance of cyto- of nonsteroidal antiinflammatory drags. N Engl J toxin-associated gene A status of Helicobacter Med 1992;

327:749—54.

pylori among non-steroidal anti-inflammatory 338. Lipworth L., Friis S., Blot W.J. et al. A popu drug users with peptic ulcer bleeding: a multicen- lation-based cohort study of mortality among ter case-control study. Scand J Gastroenterol users of ibuprofen in Denmark. Am J Ther 2004;

39:1180—5. 2004;

11:156—63.

327. Griffin M., Piper J., Daugherty J. et al. Non 339. Сороцкая В.Н., Каратеев А.Е. Желудоч steroidal anti-inflammatory drug use and но-кишечные осложнения как одна из при increased risk for peptic ulcer disease in elderly чин смерти больных ревматическими заболе persons. Ann Int Med 1991;

114:257—63. ваниями. Научно-практ ревматол 2005;

4:34–8.

328. Garcia Rodriguez L., Jick H. Risk of upper 340. Thomsen R., Riis A., Christensen S. et al.

gastrointestinal bleeding and perforation associat- Outcome of peptic ulcer bleeding among users of ed with non steroidal anti-inflammatory drugs. traditional non-steroidal anti-inflammatory drugs Lancet 1994;

343:769—72. and selective cyclo-oxygenase-2 inhibitors.

329. Langman M., Weil J., Wainwright P. et al. Aliment Pharmacol Ther 2006;

15;

24(10):1431—8.

Risk of bleeding peptic ulcer associated with indi- 341. Thomsen R., Riis A., Munk E. et al. 30-day vidual non-steroidal anti-inflammatory drugs. mortality after peptic ulcer perforation among Lancet 1994;

343:1075—8. users of newer selective COX-2 inhibitors and tra 330. Perez Gutthann S., Garcia Rodriguez L., ditional NSAIDs: a population-based study. Am J Raiford D. Individual NSAIDs and other risk fac- Gastroenterol 2006;

101(12):2704—10.

tor for upper gastrointestinal bleeding and perfo- 342. Lain L. Proton pump inhibitor co-therapy ration. Epidemiology 1997;

8:18—24. with nonsteroidal anti-inflammatory drugs-nice or 331. Garcia Rodriguez L., Cattaruzzi C., necessery? Rew Gastroenterol Dis 2004;

4:33—41.

Troncon M., Agostinis L. Risk of hospitalization 343. Каратеев А.Е., Насонова В.А. Развитие и for upper gastrointestinal tract bleeding associated рецидивирование язв желудка и двенадцати with ketorolac, other NSAIDs, calcium antago- перстной кишки у больных, принимающих nists, and other antihypertensive drugs. Arch нестероидные противовоспалительные препа раты: влияние стандартных факторов риска. trolled trials. BMJ 2002;

325:1—8.

Тер арх 2008;

5:62–6. 354. Farkouh M., Kirshner H., Harrington R.

344. Henry D., Lim L., Garcia Rodriguez L. et al. Comparison of lumiracoxib with naproxen and Variability in risk of gastrointestinal complications ibuprofen in the Therapeutic Arthritis Research with individual non-steroidal anti-inflammatory and Gastrointestinal Event Trial (TARGET), car drugs: results of a collaborative meta-analysis. diovascular outcomes: randomized controlled BMJ 1996;

312:1563—6. trial. Lancet 2004;

364:675—84.

345. Richy F., Bruyere O., Ethgen O. et al. Time 355. Rachme E., Bardou M., Dasgupta K. et al.

dependent risk of gastrointestinal complications Hospitalisation for gastrointestinal bleeding asso induced by non-steroidal antiinflammatory drug ciated with nonsyeroidal anti-inflammatory drugs use: result of a collaborative meta-analysis. Ann among eldery patients using low-dose aspirine: a Rheum Dis 2004;

63:759. retrospective cohort study. Rheumatology 346. Hippisley-Cox J., Coupland C., Logan R. (Oxford) 2007;

46:265—72.

Risk of adverse gastrointestinal outcomes in 356. Moore R., Derry S., Makinson G., McQuay H.

patients taking cyclo-oxygenase-2 inhibitor or Tolerability and adverse events in clinical trials of conventional non-steroidal anti-inflammatory celecoxib in osteoarthritis and rheumatoid arthri drugs: population based nested case-control tis: systemic review and meta-analysis on infor analysis. BMJ 2005;

331:1310—6. mation from company clinical reports. Arthritis 347. Forrest J., Camu F., Greer I. et al. Res Ther 2005;

7:644—65.

Ketorolac, diclofenac, and ketoprofen are equally 357. Biskupiak J., Brixner D., Howard K., safe for pain relief after major surgery. British J Oderda G. Gastrointestinal complications of Anaest 2002;

88:227—33. over-the-counter nonsteroidal antiinflammatory 348. MacDonald T., Morant S., Goldstein J. et al. drugs. J Pain Palliat Care Pharmacother Channelling bias and the incidence of gastroin- 2006;

20(3):7—14.

testinal haemorrhage in users of meloxicam, cox- 358. Goldstein J., Aisenbeg J., Berger M. et al.

ibs, and older, non-specific non-steroidal anti- Effects of concominant aspirin (81 mg) 0n inci inflammatory drugs. Gut 2003;

52(9):1265—70. dence the of gastric and/or duodenal ulcers in 349. Karateev A. Gastrointestinal safety of selec- healthy subjects taking celecoxib or naproxen: a tive COX-2 inhibitors in clinical practice. Annuals randomized placebo-controlled trial. Ann Rheum European Congress EULAR 2005;

64 (suppl 3), Dis 2006;

65 (Suppl II): 229 (TH0327 abstr).

SAT0117. 359. Chen Y., Jobanputra P., Barton P. et al.

350. Каратеев А.Е., Насонов Е.Л. Профилак- Cyclooxygenase-2 selective non-steroidal anti тика сосудистых тромбозов и риск желудоч- inflammatory drugs (etodolac, meloxicam, cele но-кишечных осложнений. Тер арх coxib, rofecoxib, etoricoxib, valdecoxib and 2007;

5:23–9. lumiracoxib) for osteoarthritis and rheumatoid 351. Derry S., Loke Y. Risk of gastrointestinal arthritis: a systematic review and economic evalu haemorrhage with long term use of aspirin: meta- ation. Health Technol Assess 2008;

12(11):1—278.

analysis. BMJ 2002;

521:1183—7. 360. Hawkey C. Cyclooxygenase inhibition:

352. Silverstein F., Faich G., Goldstein J. et al. between the devil and deep blue see. GUT Gastrointestinal toxicity with celecoxib versus 2002;

50:1125—30.

nonsteroidal anti-inflammatory drugs for 361. Simon L. The COX 2 Selective Inhibitors osteoarthritis and rheumatoid arthritis: the What the Newspapers Have Not Told You. Bull CLASS study: a randomized controlled trial. NYU Hospital Joint Diseases 2007;

65(3):229—41.

Celecoxid long-term arthritis safety study. JAMA 362. Singh G., Fort J., Goldstein J. et al.

2000;

284:1247—55. Celecoxib versus naproxen and diclofenac in 353. Deeks J., Smith L., Bradley M. Efficacy, tol- osteoarthritis patients: SUCCESS-1 study. Am J erability, and upper gastrointestinal safety of cele- Med 2006;

119:255—66.

coxib for treatment of osteoarthritis and rheuma- 363. Hawkey C., Kahan A., Steinbruck K. et al.

toid arthritis: systemic review of randomized con- Gastrointestinal tolerability of meloxicam com pared diclofenac in osteoarthritis patients. review of randomizes controlled trials. Am J Med International MELISSA Study Group. 1999;

107(6A):48—54.

Meloxicam Large-scale International Study Safety 373. Mellemkjaer L., Blot W., Sorensen H. et al.

Assessment. Br J Rheumat 1998;

37:1142—7. Upper gastrointestinal bleeding among users of 364. Dequerker J., Hawkey C., Kahan A. et al. NSAIDs: a population-based cohort study in Improvement in gastrointestinal tolerability of Denmark. Br J Clin Pharmacol 2002;

53:173-81.

selective cyclooxyenase (COX)-2 inhibitor, 374. Go M. Drug Injury in the upper gastroin meloxicam, compared with piroxicam: results of testinal tract: nonsteroidal anti-inflammatory the Safety and Efficacy Large Scale Evaluation of drugs. Gastrointest. Endoskopy Clin North Amer COX inhibiting Therapies (SELECT) trial in 2006;

16:83—97.

osteoarthritis. Br J Rheumatol 1998;

37:946—51. 375. Kimmey M. Role of endocopy in nons 365. Yocum D., Fleischmann R., Dalgin P. Safety teroidal anti-inflammatory drug clinical trials. Am and efficacy of meloxicam in the treatment of J Med 1998;

105:28—31.

osteoarthritis. Arch Intern Med 200;

160:2947—54. 376. Graham D., White R., Morelend L.

366. Furst D., Kolba K., Fleischmann R. Dose Duodenal and gastric ulcer prevention with miso response and safety study of meloxicam up to prostol in arthritis patients taking NSAIDs. Ann 22.5 mg daily in rheumatoid arthritis: a 12 week Inter Med 1993;

119:257—62.

multicenter, double blind, dose response study 377. Raskin J., White R., Jackson J. Misoprostol versus placebo and diclofenac. J Rheumatol dosage in the prevention of nonsteroidal anti 2002;

29:436—46. inflammatory drug-induced gastric and duodenal 367. Conforti A., Leone R., Moretti U., Velo G. ulcers: a comparson of three regimens. Ann Adverse drug reactions related to the use of Intern Med 1995;

123:344—50.

NSAIDs with a focus on nimesulide: results of 378. Cullen D., Bardhan K., Eiser M. et al.

spontaneous reporting from a Northern Italian Primary gastroduodenal prophylaxis with omepra area. Drug Saf. 2001;

24: 1081—90. zole for non-steroidal anti-inflammatory drug 368. Минушкин О.Н. Использование препа- users. Aliment Pharmacol Ther 1998;

12:135—40.

рата «Найз» у больных, страдающих сочетан- 379. Ekstrom P., Carling L., Wetterhus S. et al.

ной патологией суставов и поражением верх- Prevention of peptic ulcer and dyspeptic symp них отделов желудочно-кишечного тракта. toms with omeprazole in patients receiving con Науч-практич ревматол 2003;

5:72–6. tinuous non-steroidal anti-inflammatory drug 369. Каратеев А.Е., Каратеев Д.Е., Насонов therapy. A Nordic multicentre study. Scand J Е.Л. Гастродуоденальная переносимость ни- Gastroenterol 1996;

31:753—8.

месулида (НИМЕСИЛ, Berlin Chemie) у боль- 380. Taha A., Hudon N., Hawkey C. et al.

ных с язвенным анамнезом: первое проспек- Famotidine for the prevention of gastric and duo тивное исследование безопасности селектив- denal ulcers caused by nonsteroidal antiinflam ных ЦОГ-2-ингибиторов у больных с высо- matory drugs. N Engl J Med 1996;

334:1435—9.

ким риском развития НПВП-индуцирован- 381. Yeomans N., Tulassay Z., Juhasz L. et al.

ных гастропатий. Науч-практич ревматол A comparison of omeprazole with ranitidine for 2003;

1:45–8. ulcers associated with nonsteroidal antiinflamma 370. Bradbury F. How important is the role of the tory drugs. N Engl J Med 1998;

338:719—26.

physician in the correct use of a drug? An obser- 382. Hawkey C., Karrascch J., Szczepanski L. et vational cohort study in general practice. Int J al. Omeprazole compared with misoprostol for Clin Pract (suppl) 2004;

144:27—32. ulcers associated with nonsteroidal antiinflamma 371. Singh G., Lanes S., Triadafilopoulos G. Risk tory drugs. N Engl J Med 1998;

338:727—34.

of serious upper gastrointestinal and cardiovascu- 383. Lewis S., Langman M., Laporte J. et al.

lar thromboembolic cpmplications with meloxi- Dose-response relationship between individual cam. Am J Med 2004;

117:100—6. nonaspirin nonsteroidal anti-inflammatory drug 372. Schoenfeld P. Gastrointestinal safety profile (NANSAIDs) and serious upper gastrointestinal of meloxicam: a methaanalysis and systematic bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;

54:320—6. Effect of H. pylori status on gastric ulcer healing 384. Smalley W., Ray W., Daugherty J., Griffin in patients continuing nonsteroidal anti M. Nonsteroidal anti-inflammatory drugs and the Inflammatory therapy and receiving treatment incident of hospitalization for peptic ulcer disease with lansoprazole or ranitidine. Am J in elderly persons. Am J Epidemiol Gastroenterol 2002;

97:2208—14.

1995;

141:539—45. 397. Goldstain J., Johanson J., Suchower L., 385. Graham D., Agrawal N., Campbell D. et al. Brown K. Healing of gastric ulcers with Ulcer prevention in long-term users of nons- esomeprazole versus ranitidine in patients who teroidal anti-inflammatory drugs. Arch Intern continued to receive NSAID therapy: a ran Med 2002;

162:169—75. domised trial. Am J Gastroenterol 386. Singh G., Triadafilopoulos S. Appropriative 2005;

100:2650—7.

choice of proton pump inhibitor therapy in the 398. Маев И.В., Вьючнова Е.С., Стасева И.В.

prevention and management of NSAID-related Сравнительная оценка различных схем тера gastrointestinal damage. Int J Clin Pract пии НПВП-гастропатии. Рос ж гастроэнтерол 2005;

59:1210—5. и гепатол 2003;

3:73.

387. Lanas A. Prevention and treatment of 399. Hawkey C. J., Tullasay Z., Szczepanski L. et NSAID-induced gastrointestinal injury. Curr al. Randomised controlled trial of Helicobacter Treat Options Gastroenterol 2006;

9:147—56. pylori eradication in patients on non-steroidal 388. Graham D.Y. Nonsteroidal anti-inflammato- anti-inflammatory drugs: HELP NSAID study.

ry drugs, Helicobacter pylori, and ulcers: where Lancet 1998;

352:1016—21.

we stand. Am J Gastroenterol 1996;

96:2800—6. 400. Chan F., Sung J., Suen R. et al. Does eradi 389. Василенко В.Х., Гребенев А.Л., Шепту- cation of helicobacter pylori impair healing of лин А.А. Язвенная болезнь. Медицина, 1987. non-steroidal anti-inflammatory drug associated 390. Калинин А.В. Симптоматические гастродуо- bleeding peptic ulcers? A prospective randomized денальные язвы. Дис. … д-ра мед наук. М., 1987. study. Aliment Pharmacol Ther 1998;

12:1201—5.

391. Lanza F., Graham D., Davis R. et al. 401. Каратеев А.Е., Муравьев Ю.В., Раденска Endoscopic comparison of cimetidine and sucral- Лоповок С.Г., Насонова В.А. Эффективность fate for prevention of naproxen-induced acute антихеликобактерной терапии при НПВП gastroduodenal injury: Effect of scoring method. индуцированной гастропатии. Клин мед Dig Dis Sci 1990;

35:1494—9. 2003;

4:37–41.

392. Hawkey C., Wilson I., Naesdal J. et al. 402. Dubois R., Melmed G., Henning J., Lane L.

Influence of sex and Helicobacter pylori on devel- Guidelines for the appropriate use of non opment and healing of gastroduodenal lesion in steroidal anti-inflammatory drugs, cyclooxyge non-steroidal anti-inflammatory drug users. Gut nase-2 specific inhibitors and proton pump 2002;

51:344—50. inhibitors in patients requiring chronic anti 393. Каратеев А.Е., Дюков И.В. Факторы, inflammatory therapy. Aliment Pharmacol Ther влияющие на эффективность ингибиторов 2004;

19:197—208.

протонной помпы при НПВП-индуцирован- 403. Cryer B. COX-2-specific inhibitor or proton ных язвах желудка. Тер арх 2007;

5:37–42. pump inhibitor plus traditional NSAID: Is either 394. Tildesley G., Ensanullah R., Wood J. approach sufficient for patients at highest risk of Ranitidine in the treatment of gastric and duo- NSAID-induced ulcers? Gastroenterology denal ulcers associated with non-steroidal anti- 2004;

127:1256—62.

inflammatory drugs. Br J Rheumatol 404. Chan F., Hung L., Suen B. Celecoxib versus 1993;

32:474—8. diclofenac and omeprasole in reducing the risk of 395. Lancaster-Smith M.J., Jaderberg M.E., recurrent ulcer bleeding in patients with arthritis.

Jackson D.A. Ranitidine in the treatment of N Engl J Med 2002;

947:2104—10.

non-steroidal anti-inflammatory drug associated 405. Lai K., Chu K., Hui W. et al. Celecoxib gastric and duodenal ulcers. GUT, 1991;

252—5. compared with lansoprazole and naproxen to pre 396. Campbell D., Haber M., Sheldon E. et al. vent gastrointestinal ulcer complications. Am J Med 2005;

118:1271—8. 416. Scheiman J., Yeomans N., Talley N. et al.

406. Chan F., Wong V., Suen B. et al. Prevention of ulcer by esomeprazole in at-risk Combination of a cyclo-oxygenase-2 inhibitor patients using non-selective NSAIDs or COX- and a proton-pump inhibitor for prevention of inhibitor. Am J Gastroenterol 2006;

101:701—10.

recurrent ulcer bleeding in patients at very high 417. Материалы круглого стола: «Чего мы дос risk: a double-blind, randomised trial. Lancet тигаем, назначая ингибиторы протонной 2007;

369:1621—6. помпы, и следует ли нам опасаться широкого 407. Lazzaroni M., Sainaghi M., Bianchi Porro G. применения данных препаратов в клиниче Non-steroidal anti-inflammatory drug gastropa- ской практике?» Под ред. В.Т. Ивашкина.

thy: clinical results with antacids and sucralfate. РЖГГК 2002;

6:4–10.

Ital J Gastroenterol Hepatol 1999;

31;

48—53. 418. Kiltz U., Zochling J., Schmidt W., Braun J.

408. Robinson M., Mills R., Euler A. Ranitidine Use of NSAIDs and infection with Helicobacter prevents duodenal ulcers associated with non- pylori-what does the rheumatologist need to steroidal anti-inflammatory drug therapy. Aliment know? Rheumatology 2008;

doi:10.1093.

Pharmacol Ther 1991;

5:143—50. 419. Huang J., Sridhar S., Hunt R. Role of 409. Ten Wolde S., Dijkmans B., Janssen M. Helicobacter pylori infection and nonsteroidal High-dose ranitidine for the prevention of recur- anti-inflammatory drugs in peptic-ulcer disease: a rent peptic ulcer disease in rheumatoid arthritis meta-analysis. Lancet, 2002;

359:14—22.

patients taking NSAIDs. Aliment Pharmacol 420. Hawkey C. Editorial. Safer NSAID strate Ther 1996;

10:347—51. gies: consensus or contentious? Rheumatology 410. Silverstein F., Graham D., Senior J. et al. 2008;

47:1265—66.

Misoprostol reduces serious gastrointestinal com- 421. Chan F., Sung J., Chung S. et al.

plications in patients with rheumatoid arthritis Randomised trial of eradication of Helicobacter receiving nonsteroidal anti-inflammatory drugs. pylori before non-steroidal anti-inflammatory A randomized, double-blind, placebo-controlled drug therapy to prevent peptic ulcer. Lancet trial. Ann Intern Med 1995;

123:241—9. 1997;

350: 975—9.

411. Silverstein F. New strategies for the preven- 422. Labenz J., Blum A., Bolten W. et al. Primary tion of serious upper GI complication from prevention of diclofenac associated ulcers and NSAIDs: lessons from the MUCOSA trial. New dyspepsia by omeprazole or triple therapy in stand Arth Care 1996;

5:2—6. Helicobacter pylori positive patients: a ran 412. Raskin J., White R., Jaszewsky R. et al. domised, double blind, placebo controlled, clini Misoprostol and ranitidine in the prevention of cal trial. Gut 2002;

51:329—35.

NSAID-induced ulcers: a prospective, double- 423. Chan F., To K., Wu J. et al. Eradication of blind, multicenter study. Am J Gastroenterol Helicobacter pylori and risk of peptic ulcers in 1996;

91:223—7. patients starting long-term treatment with non 413. Agrawal N., Roth S., Graham D. et al. steroidal anti-inflammatori drugs: a randomised Misoprostol compared with sucralfate in the pre- trial. Lancet 2002;

359:9—13.

vention of nonsteroidal anti-inflammatory drug- 424. El-Serag H., Graham D., Richardson P. et induced gastric ulcer. A randomized, controlled al. Prevention of complicated ulcer disease among trial. Ann Intern Med 1991;

115:195—200. chronic users of nonsteroidal anti-inflammatory 414. Acevedo E., Castaneda O., Ugaz M. et al. drugs. Arch Intern Med 2002;

162:2105—10.

Tolerability profiles of rofecoxib (Vioxx) and 425. Chan F., Sung J., Suen B. Prospective ran Arthrotec. A comparison of six weeks treatment in domized trial of H. pylori eradication versus patients with osteoarthritis. Scand J Rheumatol maintenance omeprazole to prevent recurrent 2001;

30:19—24. upper gastrointestinal hemorrhage in high-risk 415. Lai K., Lam S., Chu K. Lansoprazole for the aspirin and nonaspirin NSAID users.

prevention of recurrences of ulcer complication Gastroenterology 2000;

118:A194.

from long-term low-dose aspirin use. N Engl J 426. Lai K., Lau C., Ip W. et al. Effect of treat Med 2002;

346:2033—8. ment of Helicobacter pylori on prevention of gas troduodenal ulcers in patients receiving long-term prevent recurrent ulcer bleeding. N Eng J Med NSAIDs: a double-blind, placebo-controlled trial. 2005;

352:238—44.

Aliment Pharmacol Ther 2000;

17:799—805. 437. Hallas J., Bytzer P. Screening for drug related 427. Malfertheiner P., Megraud F., O'Morain C. dyspepsia: an analysis of prescription symmetry.

Guidelines for the management of Helicobacter Eur J Gastroenterol Hepatol 1998;

10:27—32.

pylori infection - summary of the Maastricht-3 438. Jones J. Nonsteroidal anti-inflammatory consensus report. На сайте: Business briefing: drug-associated dyspepsia: basis mechanisms and European gastroenterology review, 2005. future research. Am J Med 2001;

110: 14—18.

428. Chan T. Adverse interaction between war- 439. Bassotti G., Bucaneve G., Furno P. et al.

farin and nonsteroidal anti-inflammatory drugs: Double-blind, placebo-controlled study on effect mechanisms, clinical significance and avoidence. of diclofenac sodium and indomethacin on post Ann Pharmacother 1994;

29:1274—83. prandial gastric motility in men. Dig Dis Sci 429. Shorr R., Ray W., Daugherty J., Griggin M. 1998;

43:1172—6.

Concurent use of non-steroidal anti-inflammato- 440. Lazzaroni M., Bianchi Porro G. Nonsteroidal ry drugs and oral anticoagulants places elderly anti-inflammatory drug gastropaty and persons at risk for hemorrhagic peptic ulcer dis- Helicobacter pylori: the search for an Improbable ease. Arch Intern Med 1993;

153:1665—70. Consensus. Am J Med 2001;

110:50—4.

430. Karim A., Tolbert D., Piergles A. et al. 441. Brun J., Jones R. Nonsteroidal anti-inflam Celecoxib does not significantly alter the pharma- matory drug-associated dyspepsia: the Scale of cokinetics or hypoprothrombinemic effect of war- the problem. Am J Med 2001;

110:12—3.

farin in healthy subjects. J Clin Pharmacol 442. Zerib F. Treatment of NSAIDs related dys 2000;

40:655—63. pepsia. Gastroenterol Clin Biol 2004;

28:73—6.

431. Knijff-Dutmer E., van der Palen J., Schut 443. MacMahon A., Evans J., White G. et al. A G., van der Laar M. The influence of cyclo-oxy- cohort study (with re-sampled comparator genase specificity of non-steroidal anti-inflamma- groups) to measure the assotiation between new tory drugs on bleeding complications in concomi- NSAID prescribing and upper gastrointestinal nant coumarine users. QJM 2003;

96:513—20. hemorrhage and perforation. J Clin Epidemiol 432. Battistella M., Mamdami M., Juurlink D. et 1997;

50:351—6.

al. Risk of upper gastrointestinal hemorrhage in 444. De Pouvourville G. The iatrogenic cost of warfarin users treated with nonselective NSAIDs non-steroidal anti-inflammatory drag therapy. Br or COX-2 inhibitors. Arch Intern Med J Rheumatol 1995;

34:19—24.

2005;

165:189—92. 445. Mamdani M., Rochon P., Juurlink D. et al.

433. Dalton S., Johansen C., Mellemkjaer L. et Observational study of upper gastrointestinal al. Use of selective serotonin reuptake inhibitors haemorrhage in elderly patients given selective and risk of upper gastrointestinal tract bleeding: a cyclo-oxygenase-2 inhibitor conventional nons population-based cohort study. Arch Intern Med teroidal anti-inflammatory drugs. BMJ 2003;

163:59—64. 2002;

325:624—7.

434. Van Walraven C., Mamdani M., Wells P. 446. Wolf F., Andarson J., Barke T. et al.

Williams J. Inhibition of serotonin reuptake by Gastroprotective therapy and risk gastrointestinal antidepressants and upper gastrointestinal bleed- ulcer reduction by COX-2 therapy. J Rheumatol ing in elderly patients: retrospective cohort study. 2002;

29:467—73.

BMJ 2001;

323:655—68. 447. Ofman J., Maclean C., Straus W. et al.

435. Sheikh R., Romano P., Prindiville T. Meta-analysis of dyspepsia and nonsteroidal anti Endoscopic evidence of mucosal injury in patients inflammatory drugs. Arthritis Rheum taking ticlopidine compared with patients taking 2003;

49:508—18.

aspirin/nonsteroidal antiinflammatory drugs and 448. Каратеев А.Е., Насонов Е.Л., Корешков Г.Г.

controls. J Clin Gastroenterol 2002;

34:529—32. НПВП-индуцированная диспепсия: распро 436. Chang F., Ching J., Huang L. et al. страненность и возможность медикаментоз Clopidogrel versus aspirin and ezomeprasole to ной коррекции. Науч-практич ревматол 2003;

5:76–8. Gastroenterology 2005;

128:1172.

449. Hawkey C, Talley N, Yemans N et al. 460. Graham D.Y., Opekun A.R., Willingham Improvements with esomeprazole in patients with F.F., Qureshi W.A. Visible small-intestinal mucos upper gastrointestinal symptoms taking non- al injury in chronic NSAID users. Clin steroidal antiinflammatory drugs, including selec- Gastroenterol Hepatol 2005;

3:55.

tive COX-2 inhibitors. Am J Gastroenterol 461. Lang J., Price A., Levi A. et al. Diaphragm 2005;

100:1028—36. disease: the pathology of non-steroidal anti 450. Laheij R., Van Rossum L., Jansen J., inflammatory drug induced small intestinal stric Verheugt F. Proton-pump inhibitor therapy for tures. J Clin Pathol 1988;

41:516—26.

acetylsalicylic acid associated upper gastrointesti- 462. Langman M., Morgan L., Worall A. Use of nal symptoms: a randomized placebo-controlled inflammatory drugs by patients admitted with trial. Aliment Pharmacol Ther 2003;

18:109—15. small or large bowel perforations and hemorrhage.

451. Лазебник Л.Б., Дроздов В.Н., Ким В.А. Br Med J 1985;

290:347—9.

Эффективность фамотидина в профилактике 463. Kessler W., Shires G., Foney T. Surgical НПВП-гастропатий. Результаты российского complications of nonsteroidal anti-inflammatory многоцентрового исследования ЗАСЛОН-1 drug-induced small bowel ulceration. J Am Coll (защита слизистой оболочки желудка от не- Surg 1997;

185:250—4.

стероидных противовоспалительных препара- 464. Bjarnason J., Prowse P., Smith T. et al. Blood тов). Экперим клин гастроэнтерол 2009;

2:3–9. end protein loss via small intestinal inflammation 452. Schaeverbeke T., Broutet N., Zerbib F. et al. induced by non-steroidal anti-inflammatory Should we eradicate Helicobacter pylori before drugs. Lancet 1987;

711—4.

prescribing an NSAID? Result of a placebo-con- 465. Hayashi Y., Yamamoto H., Kita H. et al.

trolled study. Am J Gastroenterol Non-steroidal anti-inflammatory drug-induced 2005;

100:2637—43. small bowel injuries identified by double-balloon 453. Каратеев А.Е., Насонов Е.Л. НПВП и endoscopy. World J Gastroenterol 2005;

11:61—4.

верхние отделы желудочно-кишечного тракта: 466. Adebayo D., Bjarnason I. Is nonsteroidal патология, не связанная с развитием язв и anti-inflammatory drug (NSAID) enteropathy эрозий. РМЖ 2002;

10:1318–21. clinically more impotent then NSAID gastropa 454. Каратеев А.Е., Насонова В.А. Энтеропа- thy? Postgrad Med J 2006;

82:186—91.

тия, индуцированная нестероидными проти- 467. Campbell K., Steele R. Use of anti-inflam вовоспалительными препаратами. Тер арх matory drugs and complicated diverticular dis 2003;

5:74–78. ease: a case-control study. B J Surgery 455. Davies N., Saleh J., Skjodt N. Detection and 1991;

78:190—1.

prevention of NSAID-induced enteropathy. J 468. Meyer A., Ramzan N., Heigh R., Leighton Pharm Pharm Sci 2000;

3:137—55. J. Relapse of inflammatory bowel disease associat 456. Bjarnason I., Hayllar J., MacPherson A. et ed with use of nonsteroidal anti-inflammatory al. Side effects of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 200;

51:168—72.

drugs on the small and large intestine in humans. 469. Morris A., Murray L., Sturrock R. et al.

Gastroenterology 1993;

104:1832. Short report: the effect of misoprostol on the ane 457. Morris A., Wasson L., Mac Kenzie J. Small mia of NSAID enteropathy. Aliment Pharmaco.

bowel enteroscopy in undiagnosed gastrointestinal Ther 1994;

8:343—6.

blood loss. GUT 1992;

887—9. 470. Hayllar J., Smith T., Mapherson A. et al.

458. Laine L., Connors L., Reicin A. et al. Nonsteroidal anti-inflammatory drug-induced Serious lover gastrointestinal clinical events with small intestinal inflammation and blood loss.

nonselective NSAID or coxib use. Effect of sulfasalazine and other disease - modify Gastroenterology 2003;

124:288—92. ing antirheumatic drugs. Arthritis Rheum 459. Maiden L., Thjodleifsson B., Theodors A. et 1994;

37:1146—50.

al. A Quantitative Analysis of NSAID-Induced 471. Lanas A., Scarpignato C. Microbial flora in Small Bowel Pathology by Capsule Enteroscopy. NSAID-induced intestinal damage: a role for antibiotics? Digestion 2006;

73:136—50. 483. Galati G., Tafazoli S., Sabzevari O.

472. Goldstein J., Eisen G., Lewis B. et al. Video Idiosyncratic NSAID drug induced oxidative capsule endoscopy to prospectively assess small stress. Chem Biol Interact 2002;

142:25—41.

bowel injury with celecoxib, naproxen plus 484. Каратеев А.Е., Насонова В.А. НПВП-ас omeprazole, and placebo. Clin Gastroenterol социированная гепатопатия. Клин мед Hepatol 2005;

3—13. 2004;

6:10–17.

473. Shah A., Thjodleifsson B., Murray F. et al. 485. Walker A. Quantitative studies of the risk of Selective inhibition of COX-2 in humans is asso- serious hepatic injury in persons using nons ciated with less gastrointestinal injury: a compari- teroidal antiinflammatory drugs. Arthritis Rheum son of nimesulide and naproxen. GUT 1997;

40:201—8.

2001;

48:339—46. 486. Banks A., Zimmerman H., Isshak K., Harter 474. Sigthorsson G., Crane R., Simon T. et al. J. Diclofenak-associated hepatotoxicity: analysis COX-2 inhibition with rofecoxib does not of 180 cases report to the Food and Drug increase intestinal permeability in healthy sub- Administration as adverse reactions. Hepatology jects: a double blind crossover study comparing 1995;

22:820—70.

rofecoxib with placebo and indomethacin. GUT 487. Rodrigo L., de Francisco R., Perez-Pariente 2000;

47:527—32. J. et al. Nimesulide-induced severe hemolytic 475. Sandborn W., Stenson W., Brynskov J. et al. anemia and acute liver failure leading to liver Safety of celecoxib in patients with ulcerative transplantation. Scand J Gastroenterol colitis in remission: a randomized, placebo-con- 2002;

37:1341—43 (abstr).

trolled, pilot study. Clin Gastroenterol Hepatol 488. Merlani G., Fox M., Oehen H. et al. Fatal 2006;

4:203—11. hepatotoxicity secondary to nimesulide. Eur J 476. El Miedany Y., Youssef S., Ahmed I., El Clin Pharmacol 2001;

57:321—6 (abstr).

Gaafary M. The gastrointestinal safety and effect 489. Alegria P., Lebrei L., Chagas C. Celecoxib on disease activity of etoricoxib, a selective cox-2 induced cholestatic hepatotoxicy in a patient with inhibitor in inflammatory bowel diseases. Am J cirrosis. Ann Intern Med 2002;

137:75 (abstr).

Gastroenterol 2006;

101:311—7. 490. Grieco A., Miele L., Giorgi A. Acute 477. Konturek S., Kwiecien N., Obtulowicz W. cholestatic hepatitis associated with celecoxib.

Effect of colloidal bismuth subcitrate on aspirin- Ann Pharmacother 2002;

36:1887—9 (abstr).

induced microbleeding, DNA loss, and 491. Huster D., Schubert C., Berr F. et al.

prostaglandin formation in humans. Scand J Rofecoxib-induced cholestatic hepatitis: treat Gastroenterol 1988;

23:861—6. ment with molecular absorbent recycling system 478. Kaufman H., Fischer A., Carroll M., Becker (MARS). J Hepatol 2002;

37:413—4 (abstr).

J. Colonic ulceration associated with nonsteroidal 492. McCormick P., Kennedy F., Curry M. et al.

anti-inflammatory drugs. Report of three cases. COX 2 inhibitor and fulminant hepatic failure.

Dis Colon Rectum 1996;

39:705. Lancet 1999;

353:40—1.

479. Huber T., Ruchti C., Halter F. Nonsteroidal 493. Mohammed F., Smith A.D. Cholestatic hep antiinflammatory drug-induced colonic strictures: atitis in association with celecoxib. Classification A case report. Gastroenterology 1991;

100:1119. of drug associated liver dysfunction is question 480. Kaufmann H., Taubin H. Nonsteroidal anti- able. BMJ 2002;

325:220.

inflammatory drugs activate quiescent inflamma- 494. Staelkel P., Horsmans Y. Meloxicam tory bowel disease. Ann Intern Med induced liver toxicity. Acta Gastroenterol Belg 1987;

107:513. 1999;

62:244—56 (abstr).

481. Gibson G., Whitacre E., Ricotti C. Colitis 495. Van Steenbergen W., Roskams T., Desmet V.

induced by nonsteroidal anti-inflammatory drugs. Nimesulide-induced acute hepatitis: evidence Arch Intern Med 1992;

152:625. from six cases. J Hepatol 1998;

29:135—41 (abstr).

482. Boelsterli U. Mechanisms of NSAID- 496. Tarazi E., Harter J., Zimmerman H. et al.

induced hepatotoxicity: focus on nimesulide. Sulindac-associated hepatic injury: analysis of Drug Saf 2002;

25:633—48. cases reported to the drug administration.

Gastroenterol 1993;

104:569—74. data from the Third National Health and 497. Aithal G., Day C. Nonsteroidal anti-inflam- Nutrition Examination survey. Am J Manag Care matory drug-induced hepatotoxicity. Clin Liver 2002;

8(suppl 15):83—91.

Dis 2007;

11(3):563—75. 509. Harley C., Wagner S. The prevalence of car 498. Rubenstein J., Laine L. Systematic review: diovascular risk factors in parients prescribing the hepatotoxicity of non-steroidal anti-inflam- anti-inflammatory drugs;

data from managed matory drugs. Aliment Pharmacol Ther care. Clin Ther 2003;

25:139—49.

2004;

20(4):373—80. 510. Gurwitz J.H., Avonn J., Bohn R.L. et al.

499. Sanchez-Matienzo D., Arana A. Hepatic Initiation of antihypertensive treatment deny disorders in patients treated with COX-2 selective nonsteroidal anti-inflammatory therapy. JAMA inhibitors or nonselective NSAIDs: a case/non- 1994;

272:781—6.

case analysis of spontaneous reports. Clin Ther 511. Curhan G.C., Willet W.C., Rosner B., 2006;

28(8):1123—32. Stampfer M.J. Frequency _f analgestic use and 500. Rostom A., Goldkind L., Laine L. risk of hypertension in younger woman. Arch Nonsteroidal anti-inflammatory drugs and hepat- Intern Med 2002;

162:2204—8.

ic toxicity: a systematic review of randomized 512. Dedier J., Stampfer M.J., Hankinson S.E. et controlled trials in arthritis patients. Clin al. Nonnarcotic analgetic use and risk of hyper Gastroenterol Hepatol 2005;

3(5):489—98. tension in US women. Hypertension 501. Andrade R., Lucena M., Fernandez M. et al. 2002;

40:604—8.

Drug-Induced Liver Injury: An Analysis of 461 513. Kurth T., Hennekens C.H., Sturmer T., Incidences Submitted to the Spanish Registry Sesso H.D. et al. Analgestic use and risk of subse Over a 10-Year Period. Gastroenterology quent hypertension in apparently healthy men.

2005;

129:512—21. Arch Intern Med 2005;

165:1903—9.

502. Gates B., Nguyen T., Setter S., Davies N. 514. Solomon D., Schneeweiss S., Levin R., Meloxicam: a reappraisal of pharmacokinetics, Avorn J. Relationship between COX-2 specific efficacy and safety. Expert Opin Pharmacother inhibitors and hypertension. Hypertension 2005;

6(12):2117—240. 2004;

44:140—5.

503. Maddrey W., Maurath C., Verburg K., Geis 515. Formam J., Stampfer M., Curhan G. Non G. The hepatic safety and tolerability of the novel narcotic analgetic dose and risk of incident hyper cyclooxygenase-2 inhibitor celecoxib. Am J Ther tension in US women. Hypertension 2000;

7(3):153—8. 2005;

46:500—7.

504. Traversa G., Bianchi C., Da Cas R. et al. 516. Pope J., Anderson J., Felson D. A meta Cohort study of hepatotoxity associated with analysis of the effects of nonsteroidal anti-inflam nimesulide and other non-steroidal anti-inflam- matory drugs on blood pressure. Arch Intern Med matory drugs. BMJ 2003;

327:18—22. 1993;

153:477—84.

505. Rainsford K. An analysis from clinico-epi- 517. Johnson A., Nguyen T., Day R. Do nons demiological data of the principal adverse events teroidal anti-inflammatory drugs affect blood from the COX-2 selective NSAID, nimesulide, pressure? A meta-analysis. Ann Intern Med with particular reference to hepatic injury. 1994;

121:289—300.

Inflammo - pharmacology 1998;

6:203—21. 518. Aw T.-J., Haas S., Liew D. Meta-analysis of 506. Harris C., Breyer M. Update on cyclooxygenase-2 inhibitors and their effects on Cyclooxygenase-2 Inhibitors. Clin J Am Soc blood pressure. Arch Intern Med 2005;

165:490—6.

Nephrol 2006;

1:236—45. 519. Cannon C., Curtis S., FitzGerald G. et al.

507. Cheng H.-F., Harris R. Cyclooxygenases, the Cardiovascular outcomes with etoricoxib and kidney, and hypertension. Hypertension diclofenac in patients with osteoarthritis and 2004;

43:525—30. rheumatoid arthritis in the Multinational 508. Singh G., Miller J.D., Lee F.H. et al. Etoricoxib and Diclofenac Arthritis Long-term Pevalence of cardiovascular disease risk factors (MEDAL) programme: a randomised compari among US adults with self-reported osteoarthritis: son. Lancet 2006;

18;

368(9549):1771—81.

520. Sowers J., White W., Pitt B. et al. The effects 530. Wong D., Spence J., Lamki L. et al. Effect of of cycloxygenase -2 inhibitors and nonsteroidal nonsteroidal antiinflammatory drugs on control of anti-inflammatory therapy on 24-houar blood hypertension of beta-blockers and diuretics.

pressure in patients with hypertension, Lancet 1986;

1:997—1001.

osteoarthritis, and type 2 diabetes mellitus. Arch 531. Ylitalo P., Pikajava T., Pyykonen M. et al.

Intern Med 2005;

165:161—8. Inhibition of prostaglandin synthesis by 521. Brown J., Dollery C., Valdes G. Interaction indomethacin interacts with the antihypertensive of nonsteroidal antiinflammatory drugs with anti- effect of atenolol. Clin Pharmacol Ther hypertensove and diuretic agents. Am J Med. 1985;

38:443—9.

1986;

81(suppl 2B):43—57. 532. Baez M., Alvarez C., Weilder D. Effects of 522. Durao V., Martins Prata M., Pires- the non-steroidal anti-inflammatory drugs, pirox Goncalves L.M. Modification of antihypertensive icam or sulindac, on the antihypertensive action effect of beta-adrenoreceptor-blocking agents by of propranolol and verapamil. J Hypertension inhibition of endogenous prostaglandin synthesis. 1987;

suppl. 5:563—6.

Lancet 1977;

ii:1005—7. 533. Cinquegrani M., Liang C. Antihypertensive 523. Lopez-Ovejero J.A., Weber M.A., Drayer effects of pinacidil in patients with and without J.I.M. et al. Effects of indomethacin alone and indomethacin pretreatment. Clin Exp during diuretic or beta-adreno-receptor blockade Hypertension 1988;

10:411—31.

therapy on blood pressure and the renin system in 534. Hardy B., Bartle W., Myers M. et al. Effects essential hypertension. Clin Sci Mol Med of indomethacin on the pharmakokinetics of 1978;

55:203—5. felodipine. Br J Clin Pharmacol 1988;

26:557—67.

524. Oates J.A. Antagonism of antihypertensive 535. Houston M., Weir M., Gray J. et al. The drug therapy by non-steroidal anti-inflammatory effects of non-steroidal antiinflammatory drugs drugs. Hypertension 1988;

11(suppl II):II4—II6. on blood pressure of patients with hypertension 525. Quilley J., Duchin K., Hudes E., McGiff J. controlled by verapamil. Arch Intern Med The antihypertensive effect of captopril in essen- 1995;

155:1049—54.

tial hypertension. Relationship to prostaglandins 536. Klassen D., Goadfriend T., Schuma A. et al.

and kallikrein-kinin system. J Hypertension Assesment of Blood pressure during treatment 1987;

121—8. with naproxen of ibuprofen in hypertensive 526. Salvetti A., Pedrinalli R., Magagna A., patients treated with hydrochlorthiazide. J Clin Ugenti P. Differential effects of selective and non- Pharmacol 1993;

33:1049—54.

selective prostaglandin-synthesis inhibition on 537. Johnson D., Hisel T., Phillips B. Effect of pharmacological response to captopril in patients cyclooxygenase-2 inhibitors on blood pressure.

with essential hypertension. Clin Sci Ann Pharmacother 2003;

37:442—6.

1982;

63:261—3. 538. Whelton A., Fort J., Puma J. et al. SUC 527. Silberbauer K., Stanek B., Templ H. Acute CESS VI Study Group. Cyclooxygenase-2-specif hypotensive effect of captopril in man modified by ic inhibitors and cardiorenal function: a random prostaglandin synthesis inhibition. Br. J. Clin. ized, controlled trial of celecoxib and rofecoxib in Pharmacol. 1982;

14: 87—93. older hypertensive osteoarthritis patients. Am J 528. Watkins J., Abbott E., Hensby C. et al. Ther 2001;

8:85—95.

Attenuation of hypotensive effect of propranalol 539. Whelton A., White W., Bello A. et al. SUC and thiaside diuretics by indomethacin. Br Med J CESS VII Investigators. Effects of celecoxib and 1980;

281:702—5. rofecoxib on blood pressure and edema in patients 529. Polonia J., Boaventure J., Gama G. et al. 65 years of age with systolic hypertension and Influence of nonsteroidal antiinflammatory drugs osteoarthritis. Am J Cardiol 2002;

90:959—63.

on renal function and 24-hour blood pressure- 540. White W., Kent J, Taylor A. et al. Effects of reducing effects of enalapril and nifedipine gas- celecoxib on ambulatory blood pressure in hyper trointestinal therapeutic system in hypertensive tensive patients on ACE inhibitors. Hypertension patients. J Hypertens 1995;

13:925—31. 2002;

39:929—34.

541. Dilger K., Herrlinger C., Peters J. et al. 2005;

352(11):1092—102.

Effects of celecoxib and diclofenac on blood pres- 552. Solomon S., McMurray J., Pfeffer M. et al.

sure, renal function, and vasoactive prostanoids in For the Adenoma Prevention with Celecoxib young and elderly subjects. J Clin Pharmacol (APC) Study Group. New Engl J Med 2005;

2002;

42:985—94. 352(11):1171—80.

542. Мазуров В.И., Лила А.М. Отчет о резуль- 553. Pfizer statement on new information regard татах пилотного исследования по сравнитель- ing cardiovascular safety of Celebrex.

ной оценке влияния найза (нимесулида) и ди- http://www.pfizer.com/are/investors_release/ клофенака на гемодинамические показатели у pr/mn_2004_1217.cfm.2005.

больных остеоартрозом в сочетании с эссен- 554. Use of non-steroidal anti-inflammatory циальной артериальной гипертензией. Ка- drugs suspendent in large Alzheimer`s disease pre федра терапии 1 им. Э.Э.Эйхвальда с курсом vention trial. http:/nih.gov/news/pr/dec2004/0d ревматологии Медицинской академии после- 20.htm 2004.

дипломного образования. СПб, 2007. 555. Nussmeier N., Whelton A., Brown M. et al.

543. Jick S. The risk of gastrointestinal bleeding, Complications of the COX-2 inhibitors parecoxib myocardial infarction, and newly diagnosed and valdecoxib after cardiac surgery. New Engl J hypertension in users of meloxicam, diclofenac, Med 2005;

352(11):1081—91.

naproxen, and piroxicam. Pharmacotherapy 556. Ott E., Nussmeier N., Duke P. et al. Efficacy 2000;

20:741—4. and safety of the cyclooxygenase 2 inhibitors 544. Suisa S., Bernatsky S., Hudson M. parecoxib and valdecoxib in patients undergoing Antirheumatic drug use and the risk of acute coronary artery bypass surgery. J Thorac myocardial infarction. Arthritis Rheum (Arthritis Cardiovasc Surg 2003;

125:1881—92.

Care&Res) 2006;

55:531—6. 557. Singh G., Mithal A., Triadafilopoulos G.

545. Mukherjee D., Nissen S., Topol E. Risk of Both selective COX-2 inhibitors and non-selective cardiovascular events associated with selective NSAIDs increase the risk of acute myocardial COX-2 inhibitors. JAMA 2001;

286:95495. infarction in patients with arthritis;

selectivity is 546. Baigent C., Patrono C. Selective cyclooxyge- with patients, not the drug. EULAR 2005;

nase 2 inhibitors, aspirin, and cardiovascular disease. Vienna, Austria: OP0091.

A reappraisal. Arthritis Rheum 2003;

48:12—20. 558. Hippisley-Cox J., Coupland C. Risk of 547. Juni P., Nartey L., Reichenbach S. et al. Risk myocardial infarction among patients taking of cardiovascular events and rofecoxib: cumulative cyclo-oxygenase-2 inhibitors or conventional meta-analysis. Lancet 2004;

364(9450):2021—9. non-steroidal anti-inflammatory drugs: a popula 548. McAdam B., Catella-Lawson F., Mardini I. tion based nested control study. BMJ et al. Systemic biosynthesis of prostacyclin by 2005;

330:1366—72.

cyclooxygenase (COX)-2: the human pharmacol- 559. Johnsen S., Larsson H., Tarone R. et al. Risk ogy of a selective inhibitors of COX-2. PNAS hospitalization for myocardial infarction among 1999;

96:272—7. users of rofecoxib, celecoxib, and other NSAID: a 549. Cheng Y., Austin S., Rocca B. et al. Role of population-based case-control study, Arch Intern prostacyclin in the cardiovascular response to Med 2005;

165—84.

thromboxane A2. Science 2002;

296:539—41. 560. Gislason G.H., Jacobsen S., Rasmussen J.N.

550. Grosser T., Fries S., FitzGerald G.A. et al. Riskof death or reinfarction associated with Biological basis for the cardiovascular conse- the use of selective cycloxygenase-2 inhibitors and quences of COX-2 inhibition: therapeutic chal- nonselective nonsteroidal anti-inflammatory lenes an opportunities. J Clin Invest 2006;

16:4. drugs after acute myocardial infarction.

551. Bresalier R., Sandler R., Quan H. et al. for Circulation 2006;

113:2906—13.

the Adenomatous Polyp Prevention on Vioxx 561. Chan A.T., Manson J.A., Albert C.M. et al.

(APPROVEe) Trial Investigators. Cardiovascular Nonsteroidal anti-inflammatory drugs, aceta events associated with rofecoxib in a colorectal minofen, and the risk of cardiovascular events.

adenoma chemoprevention trial. New Engl J Med Circulation 2006;

113(12):1578—87.

562. Huang W.-F., Hsiao F.-Y., Tsai Y.-W. et al. stroke. A nested case-control study. Stroke Cardiovascular events associated with long-term 2006;

37(7):1725—30.

use of celecoxib, rofecoxib and meloxicam in 573. Levesque L., Brophy J., Zhang B. The risk Taiwan. An observational study. Drug Safety for myocardial infarction with cycloxygenase- 2006;


29:261—72. inhibitors;

a population study of eldery adults.

563. Garcia Rodriguez L., Gonzalez-Perez A. Ann Intern Med 2005;

142:481—9.

Long-term use of nonsteroidal anti-inflammatory 574. Solomon D., Glynn R., Rothman K. et al.

drugs and the risl of myocardial infarction in the Subgroup Analyses to Determine Cardiovascular generalm population. BMC Medicine 2005;

3:17. Risk Associated With Nonsteroidal 564. Helin-Salmivaara A., Virtanen A., Vesalainen Antiinflammatory Drugs and Coxibs in Specific R. et al. NSAID use and the risk of hospatalisa- Patient Groups. Arthritis & Rheum tion for first myocardial infarction in the general 2008;

59(8):1097—104.

population: a national case-control study from 575. Mamdani M., Rochon P., Juurlink D. et al.

Finland. Eur Heart J 2006;

27:1657—63. Effect of selective cyclooxygenase 2 inhibitors and 565. Caldwell B., Aldinston S., Weatherell M. naproxen on short term risk of acute myocardial Risk ofcardiovascular events and celecoxib: a sys- infarction in the elderly. Arch Intern Med tematic rewiv and meta-analisis. J R Soc Med 2003;

163:481—6.

2006;

99:132—40. 576. Shaya F., Blume S., Blanchette C. et al.

566. Andersohn F., Suissa S., Garbe E. Use of Selective cycloxygenase inhibition and cardiovas first-and second-generation cyclooxygenase-2- cular effects. Arch Intern Med 2005;

165:181—6.

selective nonsteroidal antiinflammarory drugs and 577. Fisher L., Schlinger R., Matter C. et al.

risk of acute myocardial ingarction. Circulation Discontinuation of nonsteroidal anti-inflamatory 2006;

113:1950—7. drug therapy and risk of acute myocardial infarc 567. Graham D., Campen D., Hui R. et al. Risk tion. Arch Intern Med 2004;

164:2472—6.

of acute myocardial infarction and sudden cardiac 578. Fisher L., Schlienger R., Matter C. et al.

death in patients treated with cyclo-oxygenase 2 Current use nonsteroidal antiinflammatory drugs selective and non-selective non-steroidal anti- and risk of acute myocardial infarction.

inflammatory drugs: nested case control-study. Pharmacotherapy 2005;

25:503—10.

Lancet 2005;

579. Garcia Rodriguez L., Varas-Lorenz C., http://image.thelancet.com/extras/05art1005web.pdf Maguire A., Gonzalez-Perez A. Nonsteroidal 568. Solomon D., Glyn R. Relaionship between anti-inflammatory drugs and the risk of myocar selective cyclooxigenase-2 inhibitor and acute dial infarction in the general population.

myocardial infarction. Circulation Circulation 2004;

109:3000—6.

2004;

109:2068—73. 580. Kimmel S., Berlin J., Kinman J. et al.

569. Ray W., Stein C., Daugherty J. et al. COX-2 Parental ketorolac and risk of myocardial infarc selective non-steroidal anti-inflammatory drugs tion. Pharmacoepidemiol Drug Safe and risk of serious coronary heart disease. Lancet 2002;

11:113—9.

2002;

360:1071—3. 581. Schlienger R., Jick H., Meiet C. Use of non 570. Kimmel S., Berlin J., Reilly M. et al. steroidal anti-inflammatory drugs and the risk of Patients exposed to rofecoxib and celecoxib have first -time acute myocardial infarction. Br J Clin different odds of nonfatal myocardial infarction. Pharmacol 2002;

54:481—9.

Ann Intern Med 2005;

142:481—9. 582. Watson D., Rhodes T., Cai B., Guess H.

571. Solomon D., Avorn J., Glynn R., Sturmer T. Lower risk of thromboembolic cardiovascular The risk of cardiovascular events in new users of events with naproxen among patients with coxibs or NSAID. Arthritis Rheum rheumatoid arthritis. Arch Intern Med 2005;

54:1378—89. 2002;

162:1105—10.

572. Andersohn F., Schade R., Suissa S., Garbe 583. Rahme E., Pilote L., LeLorier J. Association E. Cyclooxygenase-2 selective nonsteroidal anti- between naproxen use and protection against inflammatory drugs and the risk of ischemic acute myocardial infarction. Arch Intern Med 2002;

162:1111—5. without ST-segment elevation, the NUT-2 pilot 584. Solomon D., Glynn R., Levin R., Avarn J. study. Circulation 2002;

106:191—95.

Nonsteroidal anti-inflammatory drug use and 594. White W., Borer J., Gorelic P. et al.

acute myocardial infarction. Arch Intern Med Cardiovascular events in clinical trials involving 2002;

162: 1099—4. over 41000 patients evaluating the cyclooxyge 585. Kimmel S.E., Berlin J.A., Reilly M. et al. nase-2 inhibitor celecoxib. Amer Coll Cardiology The effects of nonselective non-aspirin non- 2006;

March 11—14, Atlanta.

steroidal anti-inflammatory medications on the 595. Kearney P., Baigent C., Godwin J. et al. Do risk of nonfatal myocardial infarction and their selective cycloxygenase-2 inhibitors and tradition interaction with aspirin. J Am Coll Cardiol al non-steroidal anti-inflammatory drugs increase 2004;

43:985—90. the risk of atherothrombosis? Meta-analysis of 586. Ko D., Wang Y., Berger A. et al. randomized trials. BMJ 232:332:1302.

Nonsteroidal anti-inflammatory drugs after acute 596. Salpert S., Gregor P., Ormiston T. et al.

myocardial infarction. Am Heart J Meta-analysis: cardiovascular events associated 2002;

143:475—81. with nonsteroidal anti-inflammatory drugs. Am J 587. Schiffenbauer J. COX-2: FDA Analysis of Med 2006;

119:552—9.

cardiovascular thromboembolic events with etori- 597. Solomon D., Glynn R., Rothman K. et al.

coxib. FDA arthritis advisory committee meeting;

Subgroup Analyses to Determine Cardiovascular http://www.fda.gov/ohrms/dockets/ac/05/ slides/ Risk Associated With Nonsteroidal 2005—4090S2_04_FDA-Schiffenbauer_ Antiinflammatory Drugs and Coxibs in Specific files/slide0014.htm. Patient Groups. Arthritis & Rheum 588. Furberg C.D., Psaty B.M., FitzGerald C.A. 2008;

59(8):1097—104.

Parecoxib, valdecoxib, and Cardiovascular risk. 598. Chen L., Ashcroft D. Risk of myocardial Circulation 2005;

111:249. infarction associated with selective COX- 589. White W., Strand V., Richards R., Whelton A. inhibitors: Meta-analysis of randomized con Effects of the cyclooxygenase-2 specific inhibitor trolled trials. Pharmacoepidemiol Drug Saf valdecoxib versus nonsteroidal anti-inflammatory 2007;

DOI:10.1002/pds.

agents and placebo on cardiovascular thrombotic 599. Singh G., Wu O., Langhorne P., Madhok R.

events in patients with arthritis. Amer J Risk of acute myocardial infarction with nonse Therapeutics 2004;

11:244—50. lective non-steroidal anti-inflammatory drugs: a 590. Layton D., Hughes K., Harris S., Shakir S. meta-analysis. Arthritis Res & Therapy Comparison of the incidence rates of thromboem- 2006;

8:R153.

bolic events reported for patients prescribe cele- 600. Scott P., Kingsley C., Smith C. et al. Non coxib and meloxicam in general practice in steroidal anti-inflammatory drugs and myocardial Englend using Prescribe-Events Monitoring unfarction: systemic assesment of all available evi (PEM) data. Rheumatology (Oxford), 2003. dence. Rheumatology 2006;

45(suppl 1):i2(abstr).

591. Layton D., Heeley E., Hughes K., Shakir 601. Johnsen S., Pedersen L., Friis S. et al.

S.A. Comparison of the incidence rates of throm- Nonaspirin nonsteroidal antiinflammatory drugs boembolic events reported for patients prescribe and risk oh hospitalisation for intracerebral hem rofecoxib and meloxicam in general practice in orrhage. A population-Based Case-Control Study.

Englend using Prescribe-Events Monitoring Stroke 2003;

43:387—91.

(PEM) data. Rheumatology (Oxford), 2003. 602. Haag M., Bos M., Hofman A. et al.

592. Singh G., Lanes S., Triadafilopoulos G. Risk Cyclooxigenase selectivity of nonsteroidal anti of serious upper gastrointestinal and cardiovascu- inflammatory drugs and risk of stroke. Arch lar thromboembolic complications with meloxi- Inntern Med 2008;

168(11):1219—24.

cam. Am J Med 2004;

117:100—6. 603. Livio M., Del Maschio A., Certelli C., de 593. Altman R., Luciardi H.L., Muntaner J. et al. Gaetano G. Indomethacin prevents the long last Efficacy of assessment of meloxicam. A preferen- ing inhibitory effect of aspirin on human platelet tial COX-2 inhibitor in acute coronary syndromes cyclooxygenase activity. Prostaglandins 1982;

23:787—96. to watch over a patient treated with a NSAID in 604. Rao G., Johnson G., Reddy K., White J. relation to the cardiovascular and renal risk?

Ibuprofen protects platelet cycloxygenase from Presse Med 2006;

35:41—6.

irreversible inhibition by aspirin. Atherosclerosis 617. Laine L., White W., Rostom A., Hochberg 1983;

3:383—8. M. COX-2 Selective Inhibitors in the Treatment 605. Catella-Lawson F., Reilly M., Kapoor S. et al. of Osteoarthritis. Semin Arthritis Rheum Cyclooxygenase inhibitors and the antiplatelet 2008;

Jan 3 [Epub ahead of print].

effect of aspirin. N Engl J Med 2001;

345:1809—17. 618. Gislason G., Jacobsen S., Rasmussen J. et al.

606. Capone M., Sciulli M., Tacconelli S. et al. Risk of death or reinfarction associated with the Pharmacodynamic interaction of naproxen with use of selective cyclooxygenase-2 inhibitors and low-dose aspirin in healthy subjects. J Am Coll nonselective nonsteroidal antiinflammatory drugs Cardiol 2005;

45:1295—301. after acute myocardial infarction. Circulation 607. Van Solingen R.M., Rosenstein E.D., 2006;

113(25):2906—13.

Mihailescu G. et al. Comparison of the effects of 619. Strand V. Are COX-2 inhibitors preferable to ketoprofen on platelet function in the presence and non-selective non-steroidal anti-inflammatory absence of aspirin Am J Med 2001;

111:285—9. drugs in patients with risk of cardiovascular events 608. Wilner K., Rushing M., Walden C. et al. taking low-dose aspirin? Lancet 2007, 22;


Celecoxib does not affect the antiplatelet activity 370(9605), 2138—51.

of aspirin in healthe volunteers. J Clin Pharm 620. Heerdink E., Leufkens H., Herings R. et al.

2002;

42:1027—30. NSAIDs associated with increased risk of conges 609. Van Ryn J., Kink-Eiband M., Kuritsch I. et tive heart failure in eldery patients taking diuret al. Meloxicam does not affect the antiplatelet ics. Arch Intern Med 1998;

158:1108—12.

effect of aspirin in healthy male and female vol- 621. Fenestra J., Heerdink E., Grobbe D., unteers. J Clin Pharmacol 2004;

44:777—84. Stricker B. Association of nonsteroidal anti 610. Singh G., Graham D., Wang H. et al. inflammatory drugs with first occurrence of heart Concominant aspirin use reduces the risk of acute failure and with relapsing heart failure. The myocardial infarction in users of cyclooxygenase- Rottewrdam Study. Arch Intern Med 2 selective and somr non-selective nonsteroidal 2002;

162:265—70.

anti-inflammatory drugs. Ann Rheum Dis 622. Garcia-Rodriguez L., Hernandez-Diaz S.

2006;

65(suppl II):61(OP0024 abstr). Nonsteroidal anti-inflammatory drugs as a trigger 611. MacDonald T., Wei L. Effect of ibuprofen on of clinical heart failure. Epidemology cardioprotective effect of aspirin. Lancet 2003;

14:240—46.

2003;

361:573—74. 623. Hudson M., Richard H., Pilote L. Different 612. Kurth T., Glyn R., Walker A. et al. Inhibition in outcome of patients with congestive heart fail of clinical benefit of aspirin on first myocardial ure prescribed celecoxib, rofecoxib, or non infarction by non-steroidal anti-inflammatory steroidal anti-inflammatory drugs: population drugs. Circulation 2003;

108:1191—5. based study. BMJ 2005;

330:1—6.

613. Hudson M., Baron M., Rahme E., Pilote L. 624. Bernatsky S., Hudson M., Suissa S. Anti Ibuprofen may abrogate the benefits of aspirin rheumatic drug use and risk of hospitalisation for when used for secondary prevention of myocardial congestive heart failure in rheumatoid arthritis.

infarction. J Rheumatol 2005;

32:1589—93. Rheumatology 2005;

44:677—80.

614. Curtis J., Wang Y., Portnay E. et al. Aspirin, 625. Mamdani M., Juurlink D., Lee D. et al.

ibuprofen, and mortality after myocardial infarc- Cyclo-oxygenase-2 inhibitors versus non-selective tion. BNJ 2003;

27(7427):1322—3. non-steroidal anti-inflammatory drugs and con 615. Patel T., Goldberg K. Use of aspirin and gestive heart failure outcomes in eldery patients: a ibuprofen compared wit aspirin alone and the risk population-based cohort study. Lancet of myocardial infarction. Arch Intern Med 2004;

363:1751—56.

2004;

164:852—6. 626. Page J., Henry D., Consumption of NSAIDs 616. Schaeverbeke T., Heloire F., Deray G. How and the development of congestive heart failure in eldery patients: an underrecognized public health arrhythmia events. JAMA 2006;

296(13):161932.

problem. Arch Inten Med 2000;

777: 784 640. Adams D., Howie A., Michael J. et al.

627. Rossat R., Maillard M., Nussberger J. et al. NSAID and renal function. Lancet 1986;

1:57— Renal effects of selective cyclooxygenase-2 inhibi- 641. Blackshear J., Davidman M., Stillman T.

tion in normotensive salt-depleted subjects. Clin Identification of risk for renal insufficiency from Pharmacol Ther 1999;

66:76—84. NSAID. Arch Intern Med 1983;

143:1130—4.

628. Schwartz J., Vandormael K., Malice M. et al. 642. Blackshear J., Napier J., Davidman M., Comparison of rofecoxib, celecoxib, and naprox- Stillman M. Renal complications of NSAIDs:

en on renal function in elderly subjects receiving a identification and monitoring of those at risk.

normal-salt diet. Clin Pharmacol Ther Semin Arthritis Rheum 1985;

14:163—75.

2002;

72:50—61. 643. DiBona G. Prostaglandins and nonsteroidal 629. Corvin H., Bonventre J. Renal unsufficiency antiinflammatory drugs. Effects on renal hemody associated with non-steroidal antiinflammatory namics. Am J Med 1986;

80 (suppl 1A):12—21.

agents. Am Kidney Dis 1984;

4:147—52. 644. Altman R., Perez G., Sfakianakis G.

630. Schwartz A., Offermann G., Keller F. Interaction of cyclosporine A and nonsteroidal Analgesic nephropathy and renal transplantation. anti-inflammatory drugs on renal function in Nephrol Dial Transplant 1992;

7:472—32. patients with rheumatoid arthritis. Am J Med 631. Schlondorff D. Renal complications of nons- 1992;

93:369—402.

teroidal anti-inflammatory drug. Kidney Int 645. Griffin M., Yared A., Ray W. Nonsteroidal 1993;

44:643—53. anti-inflammatory drugs and acute renal failure in 632. Whelton A., Hamilton C. Nonsteroidal anti- eldery patients. Am J Epidemiol 2000;

151:488—96.

inflammatory drugs;

effect on kidney function. 646. Bouvy M., Heerdink E., Hoes A., Leufkens H.

J Clin Pharm 1991;

31:588—98. Efects of NSAIDs on the incidence of hospital 633. Weir M. Renal effect of nonselective izations for renal disfunction in users of ACE NSAIDs and coxibs. Clev Clin J Med inhibitors. Drug Safety 2003;

26:983—9.

2002;

69(supp 1):1—53. 647. Murray M., Black P., Kuzmik D. et al. Acute 634. Lee A., Cooper M., Craig J. Effects of nons- and chronic effects of nonsteroidal antiinflamma teroidal anti-inflammatory drugs on postoperative tory drugs on glomerular filtration rate in elderly renal function in adults with normal renal func- patients. Am J Med Sci 1995;

310(5):188—97.

tion. Cochrane Database Syst Rev 648. Agrawal N., Matthews C., Mazenko R. et al.

2007;

18(2):CD002765. Pharmacokinetics of etoricoxib in patients with 635. Schneider V., Levesque L., Zhang B. et al. renal impairment. J Clin Pharmacol Association of selective and conventional nons- 2004;

44(1):48—58.

teroidal antiinflammatory drugs with acute renal 649. Gottesdiener K., Agrawal N., Porras A. et al.

failure: A population-based, nested case-control Effects of renal insufficiency and hemodialysis on analysis. Am J Epidemiol 2006;

164(9):881—9. the pharmacokinetics of rofecoxib. Am J Ther 636. Huerta C., Castellsague J., Varas-Lorenzo C., 2003;

10(4):252—8.

Garcia Rodriguez L. Nonsteroidal anti-inflamma- 650. Fahrenholz J. Natural history and clinical tory drugs and risk of ARF in the general popula- features of aspirin-exacerbated respiratory disease.

tion. Am J Kidney Dis 2005;

45(3):531—9. Clin Rev Allergy Immunol 2003;

24(2):113—24.

637. Welton A., Schulman G., Wallemark C. et al. 651. Cohn J. Aspirin challenge and desensitiza Effects of celecoxib and naproxen on renal function tion for aspirin-exacerbated respiratory disease: a in eldery. Arch Intern Med 2000;

160:1465—70. practice paper. Ann Allergy Asthma Immunol 638. Swan S., Rudy D., Lasseter K. et al. Effect of 2007;

99(2):196.

cycloxygenase-2 inhibition on renal function in 652. Stevenson D. Aspirin and NSAID sensitivity.

eldery persons receivind a low-salt diet. Ann Immunol Allergy Clin North Am Intern Med 2000;

133:1—9. 2004;

24(3):491—505.

639. Zhang J., Ding E.L., Song Y. Adverse effects 653. Namazy J., Simon R. Sensitivity to nons of cyclooxygenase 2 inhibitors on renal and teroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;

89(6):542—50. Treatment of Acute Rheumatic Fever: A 654. Crofford L.J. Specific cyclooxygenase-2 Controlled Trial in Young Men. Ann Rheum Dis inhibitors and aspirin-exacerbated respiratory dis- 1961;

20(2):173—8.

ease. Arthritis Res 2003;

5:25—7. 667. Edwards J., Oldman A., Smith L. et al.

655. Eihom T. The role of cyclooxygenase-2 in Single dose oral aspirin for acute pain. Cochrane bone repair. Arthritis Res 2003;

5:5—7. Database Syst Rev 2000;

(2):CD002067.

656. Harder A., An Y. The mechanisms of the 668. Цодиков Г.В., Денисов Л.Н., Акимова inhibitory effects of nonsteroidal drugs on bone Т.Ф. Слизистая оболочка желудка при дейст healing: a concise review. J Clin Pharmacol вии на нее противоревматических медика 2003;

43:807—15. ментов – аспирина, индометацина, бруфена, 657. Kenny G. Potential renal, haematological преднизолона. Вопр ревм 1975;

4:38–45.

and allergic adverse effects associated with nons- 669. Levrat M., Lambert R. Digestive hemorrhag teroidal anti-inflammatory drugs. Drugs es & gastroduodenal ulcers caused by aspirin;

1992;

44(suppl 5):31—7. concerning 52 cases. Presse Med 658. Souter A. Controversies in the perioperative 1958;

66(87):1945—8.

use of nonsteroidal anti-inflammatory drugs. 670. Darvill F., Voegtline J., Hoffman G. Multiple Anesth Analg 1994;

79:1178—90. peptic ulcers after salicylate ingestion. Northwest 659. Strom B., Berlin J., Kinman J. et al. Med 1966;

65(6):495—7.

Parenteral ketorolac and the risk of gastrointesti- 671. Cryer B., Feldman M. Effect of very low nal and operative site bleeding. A postmarketing dose daily long-term therapy on gastric, duode surveillance study. JAMA 1996;

275:376—82. nal, and rectal prostaglandin levels and mucosal 660. Bricker S., Savage M., Hanning C. injury in healthy human. Gastroenterology Perioperative blood loss and non-steroidal anti- 1999;

117:17—25.

inflammatory drugs: an investigation using 672. Page J., Henry D.Consumption of NSAIDs diclofenac in patients undergoing transurethral and the development of congestive heart failure in resection of the prostate. Eur J Anaesthesiol elderly patients: an underrecognized public health 1987;

4:429—34. problem. Arch Intern Med 2000;

27;

160(6):777—84.

661. Wierod F., Frandsen N., Jacobsen J. et al. 673. Schr r K. Aspirin and Reye syndrome: a review Risk of haemorrhage from transurethral prostate- of the evidence. Paediatr Drugs 2007;

195—204.

ctomy in acetylsalicylic acid and NSAID-treated 674. Editorial. Reye`s syndrome and aspirin.

patients. Scand J Urol Nephrol 1998;

321:20—22. Epidemiological association and inborn errors of 662. Nikanne E., Kokki H., Salo J., Linna T. metabolism. Lancet 1987;

ii: 429—31.

Celecoxib and ketoprofen for pain management 675. Каратеев А.Е. Анальгетическая терапия.

during tonsillectomy: a placebo-controlled clini- Современный взгляд. Consilium Med cal trial. Otolaryngol Head Neck Surg 2008;

10(2):79–84.

2005;

132:287—94. 676. Hamerschlak N., Cavalcanti A.

663. Moiniche S., Romsing J., Dahl J., Tramer M. Neutropenia, agranulocytosis and dipyrone. Sao Nonsteroidal antiinflammatory drugs and the risk Paulo Med J 2005;

123(5):247—9.

of operative site bleeding after tonsillectomy: A 677. Edwards J., Meseguer F., Faura C et al.

quantitative systematic review. Anesth Analg Single-dose dipyrone for acute postoperative pain.

2003;

96:68—77. Cochrane Database Syst Rev 2001;

(3):CD003227.

664. Насонова В.А., Астапенко М.Г. Ревмато- 678. Edwards J., Meseguer F., Faura C. et al.

логия. М.: Медицина, 1989. Single dose dipyrone for acute renal colic pain.

665. EMPIRE Rheumatism Council;

multi-cen- Cochrane Database Syst Rev 2002;

(4):CD003867.

tre controlled trial comparing cortisone acetate 679. Peiro A., Martinez J., Martinez E. et al.

and acetyl salicylic acid in the long-term treat- Efficacy and tolerance of metamizole versus mor ment of rheumatoid arthritis;

results up to one phine for acute pancreatitis pain. Pancreatology year. Ann Rheum Dis 1955;

14(4):353—70. 2008;

8(1):25—9.

666. Slater J. Combined Aspirin and Cortisone 680. Soltesz S., Gerbershagen M., Pantke B. et al.

Parecoxib versus dipyrone (metamizole) for post- 1999;

39:184-5. На сайте: http://www.essential operative pain relief after hysterectomy : a drugs.org/edrug.

prospective, single-centre, randomized, double- 692. Andersohn F., Konzen C,. Garbe E.

blind trial. Clin Drug Investig. 2008;

28(7):421—8. Systematic Review: Agranulocytosis Induced by 681. Duarte Souza J., Lajolo P., Pinczowski H., Nonchemotherapy Drugs. Arch Intern Med del Giglio A. Adjunct dipyrone in association with 2007;

146:657—65.

oral morphine for cancer-related pain: the sooner 693. Garcia S., Canoniero M., Lopes G., Soriano A.

the better. Support Care Cancer Metamizole use among Hispanics in Miami:

2007;

15(11):1319—23. report of a survey conducted in a primary care 682. Torres L., Rodriguez M., Montero A. et al. setting. South Med J 2006;

99(9):924—6.

Efficacy and safety of dipyrone versus tramadol in 694. Dorr V., Cook J. Agranulocytosis and near the management of pain after hysterectomy: a fatal sepsis due to 'Mexican aspirin' (dipyrone).

randomized, double-blind, multicenter study. Reg South Med J 1996;

89(6):612—4.

Anesth Pain Med 2001;

26(2):118—24. 695. The International Agranulocytosis and 683. Tulunay F., Erg n H., G lmez S. et al. The Aplastic Anemia Study. Risk of agranulocytosis efficacy and safety of dipyrone (Novalgin) tablets and aplastic anemia study: relation to drug use in the treatment of acute migraine attacks: a dou- with special reference to analgesics. JAMA ble-blind, cross-over, randomized, placebo-con- 1986;

256:1749—57.

trolled, multi-center study. Funct Neurol 696. Ibanez L., Vidal X., Ballarin E., Laporte J.

2004;

19(3):197—202. Population-based drug-induced agranulocytosis.

684. Bigal M., Bordini C., Tepper S., Speciali J. Arch Intern Med 2005;

Apr 25;

165(8):869—74.

Intravenous dipyrone in the acute treatment of 697. Van der Klauw M., Wilson J., Stricker B.

migraine without aura and migraine with aura: a Drug-associated agranulocytosis: 20 years of randomized, double blind, placebo controlled reporting in The Netherlands (1974-1994). Am J study. Headache 2002;

42(9):862—71. Hematol 1998;

57(3):206—11.

685. Bianchi Porro G., Ardizzone S., Petrillo M., 698. Hernandez-Salazar A., Rosales S.P., Rangel Caruso I., Montrone F. Endoscopic assessment of Frausto S. et al. Epidemiology of adverse cuta the effects of dipyrone (metamizol) in comparison neous drug reactions. A prospective study in hos to paracetamol and placebo on the gastric and pitalized patients. Arch Med Res duodenal mucosa of healthy adult volunteers. 2006;

37(7):899—902.

Digestion 1996;

57(3):186—90. 699. Hernandez C., Aragones N., Estanyol N. et al.

686. Andrade S., Martinez C., Walker A. Two cases of anaphylactic shock after metamizol Comparative safety evaluation of non-narcotic given during postoperative recovery. Rev Esp analgesics. J Clin Epidemiol 1998;

51(12):1357—65. Anestesiol Reanim 2004;

51(3):168—9.

687. Ушкалова Е.А., Астахова А.В. Проблемы 700. Janke C., Schmeck J., Passani D.

безопасности анальгина. Фарматека Anaphylactic cardiocirculatory failure after intra 2003;

1(64):53–7. operative application of dipyrone. Anaesthesist 688. Andres E., Maloisel F. Idiosyncratic drug- 2003;

52(4):321—5.

induced agranulocytosis or acute neutropenia. 701. Eckle T., Ghanayim N., Trick M. et al.

Curr Opin Hematol 2008;

15(1):15-21. Intraoperative metamizol as cause for acute ana 689. Anonymous. Amynopyrine, dipyrone and agran- phylactic collapse. Eur J Anaesthesiol ulocytosis. Canad Med Ass J 1964;

91:1229—30. 2005;

22(10):810—2.

690. Maj S., Centkowski P. A prospective study of 702. Wojas-Pelc A., Setkowicz M., Kieltyka A., the incidence of agranulocytosis and aplastic ane- Bogdaszewska-Czabanowska J. Cutaneous mia associated with the oral use of metamizole changes occurring after taking non-steroidal anti sodium in Poland. Med Sci Monit 2004;

inflammatory drugs-five-years' retrospective stud 10(9):193—5. ies. Przegl Lek 2002;

59(12):968—72.

691. Schonhofer P. Dipyrone (Metamizol): 703. Karakaya G., Kalyoncu A.F. Metamizole Restored to good repute? Internistische Praxis intolerance and bronchial asthma. Allergol Immunopathol (Madr) 2002;

30(5):267—72. toxicity: A perspective from 1998 На сайте:

704. Gillis J., Brogden R. Ketorolac. A reap- www.hsph.harvard.edu.

praisal of its pharmacodynamic and pharmacoki- 716. Traversa G., Walker A.M., Ippolito F.M. et netics and therapeutics use in pain management. al. Gastroduodenal toxicity of different nonste Drug 1997;

53:139—88. roidal antiinflammatory drugs. Epidemiology 705. Rainer T.H. Cost effectiveness analysis of 1995;

6:49—54.

intravenous ketorolac and morphine for treating 717. Menniti-Ippolito F., Maggini M., Raschetti R.

pain after limb injury: double blind randomised et al. Ketorolac use in outpatients and ga-stroin controlled trial. BMJ. 2000;

321:1247—51. testinal hospitalization: a comparison with other 706. Dula D.J., Anderson R., Wood G.C. non steroidal anti-inflammatory drugs in Italy.

A prospective study comparing i.m. ketorolac with Eur J Clin Pharmacol 1998;

54:393—7.

i.m. meperidine in the treatment of acute biliary 718. Strom B.L., Berlin J.A., Kinman J.L. et al.

colic. J Emerg Med 2001;

20:121—4. Parenteral ketorolac and risk of gastrointestinal 707. Innes G.D., Groskerry P., Worhigton J. et al. and operative site bleeding. A postmarketing sur Ketorolac versus acetaminophen-codeine in the veillance study. JAMA 1996;

275:376—82.

emergancy department of acute pain. J Emerg 719. Gales B.J., Gales M.A. Death associated Med 1998;

16:549—56. with inappropriate ketorolac dosing. Ann.

708. McGuire D.A., Sanders K., Hendricks S.D. Pharmacotherapy 1995;

29:1299 (abstr).

Comparison of ketorolac and opioid analgesics in 720. Fleming B.M., Coombs D.W. Bleeding postoperative ACL reconstruction outpatient pain diathesis after perioperative ketorolac. Anesth control. Arthroscopy 1993;

9:653—61. Analg 1991;

73:235 (abstr).

709. Calmet J., Esteve C., Boada S., Gine J. 721. Feldman H.I., Kinnman J.L., Berlin J.A. et Analgesic effect of intra-articular ketorolac in al. Perenteral ketorolac: the risk for acute renal knee arthroscopy: comparison of morphine and failure. Ann Intern Med 1997;

127:493—4.

bupivacaine. Knee Surg. Sports Traumatol. Arth- 722. Меладзе З.А., Гунько В.И., Бутров А.В.

rosc 2004;

12:552—5. Применение НПВП в амбулаторной хирурги 710. Martin Carrasco C., Rodriquez Vasquez M., ческой стоматологии. В сб. тез. конференции Palacios Garsia R. A double-blind study of anal- «Клинические и теоретические аспекты бо gesic efficacy in kidney colic of the combination ли». М., 2001.

of dipyrone and spasmolytic with keto-rolac 723. Верткин А.Л., Вовк Е.И., Наумов А.В., trometamol. Arch Esp Urol 1993;

46:763—8. Горулева Е.И. Некоторые вопросы дифферен 711. Marin-Bertolin S., de Andres J., Gonzalez- циального назначения лекарственных препа Martinez R. et al. A controlled, randomized, dou- ратов для терапии острой боли. На сайте:

ble-blind study of ketorolac for postoperative www.intensive.ru.

analgesia after plastic surgery. Ann Plast Surg 724. Mauleon D., Artigas R., Garcia M., 1997;

38:478—84. Carganico G. Preclinical and clinical develop 712. Gonzalez-Garcia C.A., Ibarra-Ibarra L.G., ment of dexketoprofen. Drugs 1996;

52(suppl Barbosa-Vivanco S. Comparative study of ketora- 5):24—45.

lac and dipyrone administered orally in the treat- 725. Barbanoj M., Antonijoan R., Gich I.

ment of postoperative pain. Proc West Pha-racol Clinical pharmacokinetics of dexketoprofen. Clin Soc 1994;



Pages:     | 1 |   ...   | 4 | 5 || 7 |
 





 
© 2013 www.libed.ru - «Бесплатная библиотека научно-практических конференций»

Материалы этого сайта размещены для ознакомления, все права принадлежат их авторам.
Если Вы не согласны с тем, что Ваш материал размещён на этом сайте, пожалуйста, напишите нам, мы в течении 1-2 рабочих дней удалим его.